kwic
potential
potential
right
off
ON
322
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for potential out of >500 occurrences
545945 occurrences (No.21 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to potential]
545945 occurrences (No.21 in the rank) during 5 years in the PubMed. [cache]
| 322) Therefore rituximab may be considered as a potential therapy for PTR. |
| PMID:23634876 DOI:10.3109/09537104.2013.789842 |
| 2015 Platelets |
| * Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome. |
| - A 61-year-old man with newly diagnosed INT-1 risk myelodysplastic syndrome--refractory cytopenia with multilineage dysplasia (MDS-RCMD) was not responsive to treatment, such as androgen, thalidomide, granulocyte--colony stimulating factor (G-CSF) combined with erythropoietin (EPO), interleukin-11 (IL-11) and thrombopoietin (TPO), and became transfusion dependent. Due to repeated blood transfusions, he developed platelet transfusion refractoriness (PTR) to platelets from cross-matched donors as well as random donors. Anti-HLA class I antibodies were positive with enzyme-linked immunosorbent assay; however, HLA-compatible platelet products were unavailable. PTR was unresponsive to high-dose immunoglobulin and plasma exchange. The patient was then treated with rituximab 375 mg/m(2) on days 1 and 8, and 100 mg total dose on days 15 and 22. Already after the first dose of rituximab, the patient was able to received successful platelet transfusion from all donors. Therefore rituximab may be considered as a potential therapy for PTR. |
[
right
kwic]
(1)67  of |
(15)4 effects |
(29)2 by |
(43)2 mediator |
| (2)39 to |
(16)4 guardian |
(30)2 clinical |
(44)2 new |
| (3)35 for |
(17)4 mechanism |
(31)2 confounders |
(45)2 pathways |
| (4)14 *null* | (18)4 mechanisms |
(32)2 confounders, |
(46)2 perils |
| (5)13 in |
(19)3 adverse |
(33)2 directions |
(47)2 preventive |
| (6)10 as |
(20)3 applications |
(34)2 drug |
(48)2 risks |
| (7)10 risk |
(21)3 association |
(35)2 factors |
(49)2 than |
| (8)8 role |
(22)3 cytotoxicity |
(36)2 future |
(50)2 therapy |
| (9)8 use |
(23)3 genotoxic |
(37)2 harm |
(51)2 toxicity |
| (10)7 and |
(24)3 influence |
(38)2 hazards |
(52)2 vaccine |
| (11)7 therapeutic |
(25)3 pitfalls |
(39)2 impact |
(53)2 was |
| (12)6 benefits |
(26)3 utility |
(40)2 is |
|
| (13)5 health |
(27)3 value |
(41)2 issues |
|
| (14)5 predictors |
(28)2 biomarker |
(42)2 maximum |
add keyword
--- WordNet output for potential ---